Monopar Therapeutics Inc
Statements
Cash Flow
Monopar Therapeutics Inc (MNPR) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -3,247 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.2 | -0.5 | -0.3 | -0.3 | -1.2 | -0.8 | -0.8 | -0.8 | -0.6 | -0.7 | -1.0 | -0.7 | -0.6 | -0.7 | -1.1 | -1.0 | -1.3 | -1.2 | -1.9 | -1.4 | -1.9 | -2.0 | -2.5 | -1.3 | -2.1 | -1.3 | -2.3 | -2.1 | -1.9 | -1.5 | -1.7 | -1.7 | -1.1 | -2.0 | -5.7 | -1.1 | -2.1 | -3.4 | -3.5 | -3,247 | -3,256 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -1,508 | – | |
| – | – | – | 0.2 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.3 | 0.3 | 0.2 | 0.3 | 1.4 | 1.3 | 1.1 | 1.1 | 1.7 | 1,428 | 1,432 | |
| – | – | – | – | – | – | – | – | – | 0.2 | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.4 | 0.3 | 0.2 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | -0.2 | 0.0 | 0.0 | -0.1 | -0.1 | 0.1 | -0.1 | -0.1 | 0.3 | -0.4 | 0.1 | 0.1 | 0.7 | -0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | -0.1 | 1.2 | -0.3 | -0.4 | -0.5 | -0.2 | -0.3 | -0.3 | 0.0 | 4.1 | -4.3 | 0.0 | 0.2 | 1.4 | -0.5 | -214 | -213 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 3.0 | -4.9 | -1.0 | 3.0 | 0.0 | 3.0 | -1.0 | 0.0 | 1.0 | -14 | -0.3 | 1.2 | -2.1 | -62 | -5.6 | 4,115 | 4,046 | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | 10 | 0.5 | – | – | – | 11 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | -35 | 0.0 | -0.2 | 0.2 | -35 | |
| – | – | – | – | – | – | – | – | – | – | – | – | 0.1 | 0.1 | 0.1 | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | 1.0 | 1.0 | 7.5 | 0.0 | – | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.4 | 0.5 | 0.9 | 6.7 | 0.0 | 11 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.1 | 0.8 | 0.6 | 0.2 | 0.3 | 3.2 | 0.0 | 0.0 | 56 | -0.1 | -0.3 | 92 | -0.4 | -0.2 | -647 | -556 | |
| -0.2 | -0.5 | 0.7 | 0.7 | 6.3 | -0.8 | -0.8 | -0.8 | -0.6 | -0.7 | -1.0 | -0.8 | -0.6 | 8.7 | -0.6 | 0.0 | 5.4 | -1.2 | 9.0 | -1.4 | -2.0 | -2.0 | -2.5 | -1.4 | -2.1 | -6.1 | -2.5 | 1.5 | -1.7 | 1.8 | 0.5 | -1.7 | -0.1 | 40 | -6.1 | -0.2 | 88 | -66 | -9.3 | 214 | 227 | |
| -0.2 | -0.5 | -0.3 | -0.3 | -1.2 | -0.8 | -0.8 | -0.8 | -0.6 | -0.7 | -1.0 | -0.7 | -0.6 | -0.7 | -1.1 | -1.0 | -1.3 | -1.2 | -1.9 | -1.4 | -1.9 | -2.0 | -2.5 | -1.3 | -2.1 | -1.3 | -2.3 | -2.1 | -1.9 | -1.5 | -1.7 | -1.7 | -1.1 | -2.0 | -5.7 | -1.1 | -2.1 | -3.4 | -3.5 | -3,247 | -3,256 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.